Renaissance Capital logo

Rapport Therapeutics Priced, Nasdaq: RAPP

Phase 2-ready biotech developing small molecule therapies for CNS disorders.

Industry: Health Care

Latest Trade: $20.12 0.00 (0.0%)

First Day Return: +22.4%

Return from IPO: +18.4%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function. Our founders have made pioneering discoveries related to RAP function to form the basis of our RAP technology platform. We believe that our deep expertise in RAP biology provides an opportunity for us to interrogate previously inaccessible targets and develop CNS drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. RAP-219, our most advanced product candidate, is an AMPA receptor (“AMPAR”) negative allosteric modulator (“NAM”). RAP-219 is designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. We completed our Phase 1 trials in healthy adults to assess the safety and tolerability of RAP-219, and we intend to initiate a Phase 2a proof-of-concept trial in adult patients with drug-resistant focal epilepsy in the second or third quarter of (“mid”) 2024, with topline results expected in mid 2025.
more less
IPO Data
IPO File Date 05/17/2024
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 8.0
Deal Size ($mm) $136
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/06/2024
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 8.0
Deal Size ($mm) $136
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
Jefferies
more
Company Data
Headquarters Boston, MA, United States
Founded 2022
Employees 58
Website www.rapportrx.com

Rapport Therapeutics (RAPP) Performance